Equillium has announced another bolt-on deal to expand its pipeline tripling the size of its clinical pipeline to three drug candidates via a $329 million agreement to acquire Bioniz Therapeutics.
Experienced drug developer, most recently at Almirall, to lead Bioniz's clinical trials of novel, selective multi-cytokine inhibitors to treat immune-driven diseases caused by dysregulated cytokine signaling
IRVINE, Calif., July 20, 2020 /PRNewswire/ -- Bioniz Therapeutics, Inc., a clinical stage biopharmaceutical company developing first-in-class peptide therapeutics that selectively and simultaneously inhibit multiple cytokines to treat immuno-inflammatory diseases and cancers, today announced encouraging interim clinical data from its Phase 1/2 open-label clinical study of its lead product candidate BNZ-1 in patients with refractory Cutaneous T-Cell Lymphoma (rCTCL). BNZ-1 is a multi-cytokine inhibitor targeting interleukin (IL)-2, IL-9, and IL-15, that has been successfully studied in two phase 1 studies in healthy volunteers where it demonstrated a favorable safety profile, dose proportionality and exposure-dependent pharmacodynamic activity.